MorphoSys Announces Presentations at Upcoming American Society of Hematology Annual Meeting 2015
(Thomson Reuters ONE) -
MorphoSys AG /
MorphoSys Announces Presentations at Upcoming American Society of Hematology
Annual Meeting 2015
. Processed and transmitted by NASDAQ OMX Corporate Solutions.
The issuer is solely responsible for the content of this announcement.
MorphoSys AG (FSE: MOR; Prime Standard Segment; TecDAX, OTC: MPSYY) today
announced upcoming presentations of data on the Company's proprietary programs
at the 57(th) American Society of Hematology (ASH) Annual Meeting, being held
December 5-8, 2015 in Orlando, Florida. Presentations will feature pre-clinical
and clinical data for MorphoSys's proprietary programs MOR208 and MOR202.
"We believe the promising new pre-clinical and clinical data being presented for
our proprietary portfolio will further demonstrate the potential of MOR208 and
MOR202 as important treatment options for patients with B-cell malignancies and
multiple myeloma, respectively," commented Dr. Arndt Schottelius, Chief
Development Officer of MorphoSys AG. "We intend to start additional clinical
trials of MOR208 in combination regimens to assess the potential benefit of such
regimens for patients with CLL and DLBCL."
Phase IIa Study of Single-Agent MOR208 in Patients with Relapsed or Refractory
B-cell Non-Hodgkin's Lymphoma
The poster presentation will include updated clinical results from the MOR208
monotherapy trial in adult patients with relapsed/refractory NHL.
Abstract #1528
Poster session 624: Lymphoma: Therapy with Biologic Agents, excluding Pre-
Clinical Models
Date: Saturday, December 5, 2015, 5:30pm - 7:30pm EST (11:30pm CET, 10:30pm GMT)
A Phase II Study of the Fc Engineered CD19 Antibody MOR208 in Combination with
Lenalidomide for Patients with Chronic Lymphocytic Leukemia (CLL)
The poster presentation will include first safety and efficacy results from the
ongoing trial of MOR208 in combination with lenalidomide.
Abstract #2953
Poster session 642: CLL: Therapy, excluding Transplantation
Date: Sunday, December 6, 2015, 6:00pm - 8:00pm EST (0:00 am CET (Dec.
7), 11:00pm GMT)
Phase I/IIa Study of the Human Anti-CD38 Antibody MOR202 (MOR03087) in Relapsed
or Refractory Multiple Myeloma
The poster presentation will include updated safety and efficacy results from
the ongoing MOR202 dose-escalation study in multiple myeloma patients. Data will
be presented from the highest dose cohort of MOR202 as monotherapy, as well as
from the first two cohorts of patients receiving MOR202 in combination with
lenalidomide and pomalidomide.
Abstract #3035
Session Name: 653. Myeloma: Therapy, excluding Transplantation
Date: Sunday, December 6, 2015, 6:00pm - 8:00pm EST (0:00 am CET (Dec.
7), 11:00pm GMT)
MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal
Activity In Vivo and Shows Synergistic Efficacy in Combination with Different
Antineoplastic Compounds
Abstract #3015
Poster session 652: Myeloma: Pathophysiology and Pre-Clinical Studies, excluding
Therapy
Date: Sunday, December 6, 2015, 6:00pm - 8:00pm EST (0:00 am CET (Dec.
7), 11:00pm GMT)
Lenalidomide enhances MOR202 dependent macrophage-mediated effector functions
via the vitamin D pathway
Abstract #2203
Poster session 201: Granulocytes, Monocytes and Macrophages
Date: Sunday, December 6, 2015, 6:00pm - 8:00pm EST (0:00 am CET (Dec.
7), 11:00pm GMT)
Additional information can be found at www.hematology.org, including the
abstracts.
About MorphoSys:
MorphoSys developed HuCAL, the most successful antibody library technology in
the pharmaceutical industry. By successfully applying this and other patented
technologies, MorphoSys has become a leader in the field of therapeutic
antibodies, one of the fastest-growing drug classes in human healthcare.
Together with its pharmaceutical partners, MorphoSys has built a therapeutic
pipeline of more than 100 human antibody drug candidates for the treatment of
cancer, rheumatoid arthritis, and Alzheimer's disease, to name just a few. With
its ongoing commitment to new antibody technology and drug development,
MorphoSys is focused on making the healthcare products of tomorrow. MorphoSys is
listed on the Frankfurt Stock Exchange under the symbol MOR. For regular updates
about MorphoSys, visit http://www.morphosys.com.
HuCAL(®), HuCAL GOLD(®), HuCAL PLATINUM(®), CysDisplay(®), RapMAT(®), arYla(®),
Ylanthia(®), 100 billion high potentials(®), Slonomics(®), Lanthio Pharma(®) and
LanthioPep(®) are registered trademarks of the MorphoSys Group.
This communication contains certain forward-looking statements concerning the
MorphoSys group of companies, The forward-looking statements contained herein
represent the judgment of MorphoSys as of the date of this release and involve
risks and uncertainties, Should actual conditions differ from the Company's
assumptions, actual results and actions may differ from those anticipated,
MorphoSys does not intend to update any of these forward-looking statements as
far as the wording of the relevant press release is concerned.
For more information, please contact:
MorphoSys AG
Dr. Claudia Gutjahr-Löser
Head of Corporate Communications & IR
Alexandra Goller
Manager Corporate Communications & IR
Tel: +49 (0) 89 / 899 27-404
investors(at)morphosys.com
Media Release (PDF):
http://hugin.info/130295/R/1964589/717118.pdf
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: MorphoSys AG via GlobeNewswire
[HUG#1964589]
Unternehmensinformation / Kurzprofil:
Datum: 05.11.2015 - 16:30 Uhr
Sprache: Deutsch
News-ID 432376
Anzahl Zeichen: 6741
contact information:
Town:
Martinsried / Munich
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 225 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"MorphoSys Announces Presentations at Upcoming American Society of Hematology Annual Meeting 2015"
steht unter der journalistisch-redaktionellen Verantwortung von
MorphoSys AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
